Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04886258 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis
A Phase 2 study of Symptomatic Knee Osteoarthritis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
- 20
- Study locations
NCT04886258 is a Phase 2 study of Symptomatic Knee Osteoarthritis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 115 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT04886258, a Phase 2 study of Symptomatic Knee Osteoarthritis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a double-blinded, two-arm, phase 2a study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoarthritis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DFV890
Study Locations (20)
Other
- Novartis Investigative Site - San Miguel de Tucumán
- Novartis Investigative Site - Nový Jičín
- Novartis Investigative Site - Prague
- Novartis Investigative Site - Uherské Hradiště
- Novartis Investigative Site - Bad Doberan
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Leipzig
Florida
- IRIS Research and Development - Plantation
- Conquest Research - Winter Park
Arizona
- ARENSIA Explor Med Res Clinic - Phoenix
California
- TriWest Reserach Associates - El Cajon
Colorado
- Skylight Health Res Inc Color Spr - Colorado Springs
Georgia
- Ctr for Adv Research and Education - Gainesville
Illinois
- Northwestern University - Chicago
Buenos Aires
- Novartis Investigative Site - CABA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2024-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04886258
The ClinicalTrials.gov registry entry for NCT04886258 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Symptomatic Knee Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04886258 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04886258 about?
NCT04886258 is a clinical study titled "Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis". This was a double-blinded, two-arm, phase 2a study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoarthritis.
What is the current status of trial NCT04886258?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2021-09-20. Estimated completion is 2024-12-23.
What conditions does trial NCT04886258 study?
This clinical trial studies the following conditions: Symptomatic Knee Osteoarthritis.
What interventions are being tested in trial NCT04886258?
The interventions under investigation include: Placebo (DRUG), DFV890 (DRUG).
Who is sponsoring clinical trial NCT04886258?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04886258 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.